What is Cellivate Technologies?
Cellivate Technologies operates at the intersection of biotechnology and ethical manufacturing, specializing in innovative solutions for cell growth. The company's flagship product, Booster, is engineered to replace Fetal Bovine Serum, a component traditionally derived from animal sources that has long been a bottleneck for ethical drug development and regenerative medicine. By offering a consistent, high-quality, and cruelty-free alternative, Cellivate Technologies addresses the growing demand for sustainable inputs in the pharmaceutical, skincare, and food industries. Their market position is defined by a focus on technological precision and environmental stewardship, empowering clients to transition away from animal-derived components without compromising on performance or regulatory compliance.
How much funding has Cellivate Technologies raised?
Cellivate Technologies has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2024): $1M with participation from Venture Catalysts Uttar Pradesh, We Founder Circle, Hatcher, and Antler
Key Investors in Cellivate Technologies
Venture Catalysts Uttar Pradesh
A prominent Indian incubator providing integrated support, capital, and sector-specific expertise to early-stage startups.
We Founder Circle
A founder-first investment network that provides seed capital and business development support to early-stage ventures.
Hatcher
A technology-focused firm utilizing AI and machine learning to optimize portfolio management and investment strategies.
What's next for Cellivate Technologies?
With the infusion of this major strategic investment, Cellivate Technologies is poised to enter a phase of rapid commercial expansion and product diversification. The company intends to leverage these resources to enhance its research and development capabilities, further refining its cell growth technology to meet the evolving needs of global pharmaceutical partners. Strategic priorities include scaling production to meet international demand and strengthening its market presence in key regions. As the industry shifts toward more sustainable and ethical supply chains, Cellivate Technologies is strategically aligned to become a foundational provider for companies seeking to integrate cruelty-free practices into their core operations. This capital injection provides the necessary runway to solidify their leadership in the burgeoning field of animal-free biotechnology.
See full Cellivate Technologies company page
